News

The clinical trial, which was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, was designed to compare AstraZeneca’s Iressa (gefitinib) to placebo

Collegium’s business model is to develop differentiated, patent-protected or high barrier to entry products, complete ‘proof of concept’ studies and then out-license the products for commercialization by a

Vinorelbine tartrate 10mg (base)/mL is indicated as a single agent or in combination with cisplatin for the first line treatment of ambulatory patients with unresectable, advanced non-small cell

CHIR-12.12, a fully human, antagonist antibody that targets the CD40 antigen, is the first drug candidate to enter clinical testing under the collaborative agreement between Chiron and Xoma,

GelStat Arthritis is the company’s second over-the-counter (OTC) product and, like GelStat Migraine, utilizes the company’s patent pending formulation in combination with a sublingual (under the tongue) delivery

A total of 84,940 new shares of OSI Pharmaceuticals were issued in exchange for the 286,200 minority interest shares of Prosidion, which represents 2.7% of Prosidion shares. The

The primary purpose of the phase I clinical trial was to determine the safety, maximum tolerated dose, dose-limiting toxicities, and pharmacokinetics of HGS-ETR1 in patients with relapsed or

The preclinical studies were conducted in a melanoma mouse model, which is commonly used to evaluate experimental cancer treatments. Mice were treated with an experimental version of the

Corgentech’s novel cancer therapy, HIF Decoy, is a high affinity, specific inhibitor of both HIF-1 and HIF-2, transcription factors that play key roles in cancer cell growth, survival